ArticleBioMed research international2026
Comprehensive Experimental and Computational Characterization of a Phenylacetamide-Based Molecule.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comprehensive Experimental and Computational Characterization of a Phenylacetamide-Based Molecule.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The aim of this study was to synthesize Tetrahydroisoquinoline Derivative 1 (M1) and to evaluate its biological activities in the SH-SY5Y neuroblastoma cell line. Theoretical calculations for the investigated molecule were performed using the Gaussian software package at the B3LYP, HF, and M062X levels with the 6-31g, 6-31++g, and 6-31++g(d,p) basis sets. Subsequently, the activity of the compound against SH-SY5Y cancer-related proteins (PDB IDs: 2F37, 3PBL, and 5WIV) was assessed. In addition, the molecule-likeness properties of the molecule were evaluated through ADME/T analyses. The cytotoxic activity of M1 in the SH-SY5Y cell lines was determined using the MTT assay. Following treatment with M1, the expression levels of apoptosis-related genes (MYC, CASP2, BAX, and NF-κB1) and genes associated with DNA repair mechanisms (TP53, RAD51, BRCA2, and MDM2) were analyzed by RT-PCR. Enzyme activities were also measured in M1-treated SH-SY5Y cells. The results demonstrated that M1 exerted its highest cytotoxic effect in the SH-SY5Y cell line after 72 h of incubation. Compared with the control group, M1 showed a stronger effect on G6PDH activity in SH-SY5Y cells, while catalase activity increased by 78% following M1 treatment. Moreover, M1 markedly reduced cell viability in SH-SY5Y cells relative to the control group. In conclusion, these findings indicate that Tetrahydroisoquinoline Derivative M1 exhibits pronounced cytotoxic activity in SH-SY5Y neuroblastoma cells and significantly modulates oxidative stress-related enzyme activities as well as the expression of genes involved in apoptosis and DNA repair pathways, suggesting that M1 may represent a novel and promising candidate for neuroblastoma therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.